BACKGROUND: Depression is common in HIV-infected patients receiving antiretroviral therapy. However, longitudinal studies addressing the role that depression might play in HIV clinical progression and mortality remain rare. This is especially true for those studies that also consider the possible confounding influence of patient's adherence to treatment. METHODS: The ANRS CO-8 APROCO-COPILOTE cohort study enrolled 1,281 individuals at the initiation of a protease-inhibitor-containing regimen between 1997 and 1999. Adherence, depressive symptoms and other psychosocial factors were measured using self-administered questionnaires. Predictors of progression to AIDS or death were studied using Cox models. RESULTS: Out of 1,028 individuals eligible for the present analysis, 92 individuals either died or had an AIDS-defining event during a median follow up of 54 months. At baseline, 377 individuals (41%) reported depressive symptoms and 124 (12%) reported non-adherence at month 4. Depressive symptoms at baseline were associated with progression (hazard ratio [HR] 2.1; P = 0.001). Despite the association between depressive symptoms and nonadherence, depressive symptoms remained a predictor of clinical progression (adjusted HR [aHR] [95% confidence interval (CI)] 1.6 [1.0-2.5]) after adjustment for several factors: initial non-adherence (aHR [95% CI] 2.0 [1.1-3.6]), having a steady partner (aHR [95% CI] 0.5 [0.3-0.7]), older age (aHR [95% CI] 1.40 [1.12-1.74] per 10-year increment), HIV clinical stage C (aHR [95% CI] 2.5 [1.6-4.0]), plasma HIV RNA > or = 100,000 copies/ml (aHR [95% CI] 1.7 [1.1-2.87]) and more than 8 years since HIV diagnosis (aHR [95% CI] 1.8 [1.1-2.8]). CONCLUSION: Depressive symptoms and non-adherence are independent predictors of HIV clinical progression and mortality. Screening and appropriate treatment of depressive symptoms at antiretroviral treatment initiation should be included in the standard care of HIV-infected patients.
BACKGROUND:Depression is common in HIV-infectedpatients receiving antiretroviral therapy. However, longitudinal studies addressing the role that depression might play in HIV clinical progression and mortality remain rare. This is especially true for those studies that also consider the possible confounding influence of patient's adherence to treatment. METHODS: The ANRS CO-8 APROCO-COPILOTE cohort study enrolled 1,281 individuals at the initiation of a protease-inhibitor-containing regimen between 1997 and 1999. Adherence, depressive symptoms and other psychosocial factors were measured using self-administered questionnaires. Predictors of progression to AIDS or death were studied using Cox models. RESULTS: Out of 1,028 individuals eligible for the present analysis, 92 individuals either died or had an AIDS-defining event during a median follow up of 54 months. At baseline, 377 individuals (41%) reported depressive symptoms and 124 (12%) reported non-adherence at month 4. Depressive symptoms at baseline were associated with progression (hazard ratio [HR] 2.1; P = 0.001). Despite the association between depressive symptoms and nonadherence, depressive symptoms remained a predictor of clinical progression (adjusted HR [aHR] [95% confidence interval (CI)] 1.6 [1.0-2.5]) after adjustment for several factors: initial non-adherence (aHR [95% CI] 2.0 [1.1-3.6]), having a steady partner (aHR [95% CI] 0.5 [0.3-0.7]), older age (aHR [95% CI] 1.40 [1.12-1.74] per 10-year increment), HIV clinical stage C (aHR [95% CI] 2.5 [1.6-4.0]), plasma HIV RNA > or = 100,000 copies/ml (aHR [95% CI] 1.7 [1.1-2.87]) and more than 8 years since HIV diagnosis (aHR [95% CI] 1.8 [1.1-2.8]). CONCLUSION:Depressive symptoms and non-adherence are independent predictors of HIV clinical progression and mortality. Screening and appropriate treatment of depressive symptoms at antiretroviral treatment initiation should be included in the standard care of HIV-infectedpatients.
Authors: K So-Armah; S K Gupta; S Kundu; J C Stewart; J L Goulet; A A Butt; J J Sico; V C Marconi; S Crystal; M C Rodriguez-Barradas; M Budoff; C L Gibert; C-Ch Chang; R Bedimo; M S Freiberg Journal: HIV Med Date: 2019-03-29 Impact factor: 3.180
Authors: Carl A Latkin; Hong Van Tieu; Sheldon Fields; Brett S Hanscom; Matt Connor; Brett Hanscom; Sophia A Hussen; Hyman M Scott; Matthew J Mimiaga; Leo Wilton; Manya Magnus; Iris Chen; Beryl A Koblin Journal: AIDS Behav Date: 2017-04
Authors: Angela M Bengtson; Brian W Pence; Richard Moore; Matthew J Mimiaga; William Christopher Mathews; Amy Heine; Bradley N Gaynes; Sonia Napravnik; Katerina Christopoulos; Heidi M Crane; Michael J Mugavero Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: Mardge H Cohen; Mary Fabri; Xiaotao Cai; Qiuhu Shi; Donald R Hoover; Agnes Binagwaho; Melissa A Culhane; Henriette Mukanyonga; Davis Ksahaka Karegeya; Kathryn Anastos Journal: J Womens Health (Larchmt) Date: 2009-11 Impact factor: 2.681
Authors: Katie E Mosack; Lance S Weinhardt; Jeffrey A Kelly; Cheryl Gore-Felton; Timothy L McAuliffe; Mallory O Johnson; Robert H Remien; Mary Jane Rotheram-Borus; Anke A Ehrhardt; Margaret A Chesney; Stephen F Morin Journal: Behav Med Date: 2009 Impact factor: 3.104